Legal & General Group Plc Purchases 114,833 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Legal & General Group Plc raised its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 367.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 146,125 shares of the company's stock after purchasing an additional 114,833 shares during the period. Legal & General Group Plc's holdings in Dr. Reddy's Laboratories were worth $2,307,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares in the last quarter. POM Investment Strategies LLC lifted its stake in Dr. Reddy's Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after purchasing an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after purchasing an additional 2,093 shares during the last quarter. Independence Bank of Kentucky grew its position in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after purchasing an additional 2,220 shares in the last quarter. Finally, Allworth Financial LP increased its holdings in shares of Dr. Reddy's Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after purchasing an additional 2,230 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy's Laboratories Price Performance

NYSE:RDY traded down $0.02 during trading hours on Wednesday, reaching $13.92. The stock had a trading volume of 1,247,101 shares, compared to its average volume of 1,472,469. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a market capitalization of $11.62 billion, a PE ratio of 22.17 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The company has a 50 day moving average price of $13.20 and a two-hundred day moving average price of $14.19.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, sell-side analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.